{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:56:45Z","timestamp":1773046605704,"version":"3.50.1"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jpem-2025-0305_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Gonadotropin-releasing hormone agonists are used to suppress physical signs of puberty and improve height outcomes by decelerating bone age maturation in patients with central precocious puberty (CPP). Published data assessing biochemical and clinical parameters in patients with CPP treated with six-monthly triptorelin beyond 12\u00a0months is\u00a0scant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0305_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-seven girls with CPP were treated with 22.5\u202fmg six-monthly intramuscular triptorelin. We assessed luteinizing hormone (LH) and E2 levels throughout treatment and changes in pubertal stage, bone age (BA), and predicted adult height (PAH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0305_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>LH was suppressed in 100\u202f% of girls through 36\u00a0months on treatment, except for 2 girls with an LH &gt;4\u202fmIU\/mL at 6\u00a0months, both suppressed by 12\u00a0months and beyond. Estradiol was suppressed in all girls at all points measured. Fifty-one per cent and 32.4\u202f% had no further breast development or regression, respectively, and 16.2\u202f% had further breast development. Average BA\/CA remained at 1.2\u00a0\u00b1\u00a00.1 until 24\u00a0months, at which time it decreased to 1.1\u00a0\u00b1\u00a00.1. Height velocity over the first 12\u00a0months of treatment averaged at 5.5\u202fcm\/year\u202f\u00b1\u202f2.2\u202fcm, 4.6\u202fcm\/year\u202f\u00b1\u202f1.6 between 12 and 24\u00a0months, and 3.8\u202fcm\/year \u00b1 2.2 between 24 and 36\u00a0months. On average, PAH increased by 5.4\u00a0\u00b1\u00a05.5\u202fcm on treatment (range 1.8\u201318\u202fcm).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jpem-2025-0305_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Six-monthly intramuscular triptorelin for the treatment of CPP in girls demonstrated efficacy in LH and estradiol suppression, regression or stabilization of breast maturation, normalization of height velocity, improved BA\/CA ratio, and increased PAH, throughout 2\u00a0years of treatment and beyond.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jpem-2025-0305","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:56:02Z","timestamp":1769255762000},"page":"273-278","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24\u00a0months and beyond"],"prefix":"10.1515","volume":"39","author":[{"given":"Allison","family":"Foreman","sequence":"first","affiliation":[{"name":"University of California, San Diego and Rady Children\u2019s Hospital , San Diego , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen O.","family":"Klein","sequence":"additional","affiliation":[{"name":"University of California, San Diego and Rady Children\u2019s Hospital , San Diego , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela","family":"Vargas Trujillo","sequence":"additional","affiliation":[{"name":"University of California, San Diego and Rady Children\u2019s Hospital , San Diego , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"2026030907573189892_j_jpem-2025-0305_ref_001","doi-asserted-by":"crossref","unstructured":"Lee, PA. Central precocious puberty. an overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin N Am 1999;28:901\u201318. https:\/\/doi.org\/10.1016\/s0889-8529(05)70108-0.","DOI":"10.1016\/S0889-8529(05)70108-0"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_002","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Roger, M, Chaussain, JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135\u201347. https:\/\/doi.org\/10.1093\/humupd\/dmh012.","DOI":"10.1093\/humupd\/dmh012"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_003","doi-asserted-by":"crossref","unstructured":"Menon, PS, Vijayakumar, M. Precocious puberty-perspectives on diagnosis and management. Indian J Pediatr 2014;81:76\u201383. https:\/\/doi.org\/10.1007\/s12098-013-1177-6.","DOI":"10.1007\/s12098-013-1177-6"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_004","doi-asserted-by":"crossref","unstructured":"Carel, JC, Roger, M, Ispas, S, Tondu, F, Lahlou, N, Blumberg, J, et al.. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of decapeptyl in precocious puberty. J\u00a0Clin Endocrinol Metab 1999;84:1973\u20138. https:\/\/doi.org\/10.1210\/jcem.84.6.5647.","DOI":"10.1210\/jcem.84.6.5647"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_005","doi-asserted-by":"crossref","unstructured":"Lebrethon, MC, Bourguignon, JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 2000;12:394\u20139. https:\/\/doi.org\/10.1097\/00008480-200008000-00020.","DOI":"10.1097\/00008480-200008000-00020"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_006","doi-asserted-by":"crossref","unstructured":"Mul, D, Hughes, IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159:S3\u20138. https:\/\/doi.org\/10.1530\/eje-08-0814.","DOI":"10.1530\/EJE-08-0814"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_007","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Group, ELGACC, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_008","doi-asserted-by":"crossref","unstructured":"Klein, K, Yang, J, Aisenberg, J, Wright, N, Kaplowitz, P, Lahlou, N, et al.. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J\u00a0Pediatr Endocrinol Metab 2016;29:1241\u20138. https:\/\/doi.org\/10.1515\/jpem-2015-0376.","DOI":"10.1515\/jpem-2015-0376"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_009","doi-asserted-by":"crossref","unstructured":"Yu, X, Cheng, X, Wei, H, Xu, X, Gong, C, Li, G, et al.. A phase 3, open-label, single-arm trial of the efficacy and safety of triptorelin 6-month formulation in Chinese children with central precocious puberty. Adv Ther 2024;41:4537\u201356. https:\/\/doi.org\/10.1007\/s12325-024-02991-x.","DOI":"10.1007\/s12325-024-02991-x"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_010","doi-asserted-by":"crossref","unstructured":"Yoo, E, Kim, S, Jung, HL, Shim, JY, Shim, JW, Kim, DS, et al.. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty. Front Endocrinol 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1134977. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36875449\/.","DOI":"10.3389\/fendo.2023.1134977"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_011","doi-asserted-by":"crossref","unstructured":"Garibaldi, LR, Aceto, T, Weber, C, Pang, S. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test. J\u00a0Clin Endocrinol Metab 1993;76:851\u20136. https:\/\/doi.org\/10.1210\/jcem.76.4.8473395.","DOI":"10.1210\/jcem.76.4.8473395"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_012","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Silverman, LA. Diagnosis of central precocious puberty. Endocrinol Metab Clin N Am 2024;53:217\u201327. https:\/\/doi.org\/10.1016\/j.ecl.2024.02.002.","DOI":"10.1016\/j.ecl.2024.02.002"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_013","doi-asserted-by":"crossref","unstructured":"Klein, KO, Miller, BS, Mauras, N. Unstimulated luteinizing hormone for assessment of suppression during treatment of central precocious puberty with 6-month subcutaneous leuprolide acetate: correlations with clinical response. Horm Res Paediatr 2025;98:514\u201323. https:\/\/doi.org\/10.1159\/000539110.","DOI":"10.1159\/000539110"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_014","doi-asserted-by":"crossref","unstructured":"Klein, KO, Mauras, N, Nayak, S, Sunil, B, Martinez-Placencia, BM, Dragnic, S, et al.. Efficacy and safety of leuprolide acetate 6-Month depot for the treatment of central precocious puberty: a phase 3 study. J\u00a0Endocr Soc 2023. https:\/\/doi.org\/10.1210\/jendso\/bvad071. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37334213\/.","DOI":"10.1210\/jendso\/bvad071"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_015","doi-asserted-by":"crossref","unstructured":"Bhatia, S, Kirk Neely, E, Wilson, DM. Serum luteinizing hormone rises within minutes after depot leuprolide injection: implications for monitoring therapy. Pediatrics 2002. https:\/\/doi.org\/10.1542\/peds.109.2.e30. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11826240\/.","DOI":"10.1542\/peds.109.2.e30"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_016","doi-asserted-by":"crossref","unstructured":"Marshall, WA, Tanner, JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291\u2013303. https:\/\/doi.org\/10.1136\/adc.44.235.291.","DOI":"10.1136\/adc.44.235.291"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_017","unstructured":"Greulich, WW, Pyle, SI, editors. Radiographic atlas of skeletal development of the hand and wrist. Stanford: Stanford University Press; 1950."},{"key":"2026030907573189892_j_jpem-2025-0305_ref_018","doi-asserted-by":"crossref","unstructured":"Bayley, N, Pinneau, S. Table\u00a0for predicting adult height from skeletal age. J\u00a0Pediatr 1952;40:423\u201341. https:\/\/doi.org\/10.1016\/s0022-3476(52)80205-7.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_019","doi-asserted-by":"crossref","unstructured":"Hermanussen, M, Cole, J. The calculation of target height reconsidered. Horm Res Paediatr 2003;59:180\u20133. https:\/\/doi.org\/10.1159\/000069321.","DOI":"10.1159\/000069321"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_020","unstructured":"Kuczmarski, RJ, Ogden, CL, Guo, SS, Grummer-Strawn, LM, Flegal, KM, Mei, Z, et al.. 2000 CDC Growth Charts for the United\u00a0States: methods and development. Vital Health Stat 2002;11:1\u2013190."},{"key":"2026030907573189892_j_jpem-2025-0305_ref_021","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Aguayo, A, Hern\u00e1ndez, MI, Beas, F, I\u00f1iguez, G, Avila, A, Sovino, H, et al.. Treatment of central precocious puberty with triptorelin 11.25\u00a0mg depot formulation. J\u00a0Pediatr Endocrinol Metab 2006;19:963\u201370. https:\/\/doi.org\/10.1515\/jpem.2006.19.8.963.","DOI":"10.1515\/JPEM.2006.19.8.963"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_022","doi-asserted-by":"crossref","unstructured":"Luo, X, Zhang, C, Yang, Y, Xu, X, Cheng, X, Wei, H, et al.. Efficacy and safety of triptorelin 3-month formulation in Chinese children with central precocious puberty: a phase 3, open-label, single-arm study. Adv Ther 2023;40:4574\u201388. https:\/\/doi.org\/10.1007\/s12325-023-02617-8.","DOI":"10.1007\/s12325-023-02617-8"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_023","doi-asserted-by":"crossref","unstructured":"Carel, JC, Blumberg, J, Seymour, C, Adamsbaum, C, Lahlou, N. Three-month sustained-release triptorelin (11.25\u00a0mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119\u201324. https:\/\/doi.org\/10.1530\/eje.1.02056.","DOI":"10.1530\/eje.1.02056"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_024","doi-asserted-by":"crossref","unstructured":"Neely, EK, Silverman, LA, Geffner, ME, Danoff, TM, Gould, E, Thornton, PS, et al.. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol 2013. https:\/\/doi.org\/10.1186\/1687-9856-2013-20. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24295437\/.","DOI":"10.1186\/1687-9856-2013-20"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_025","doi-asserted-by":"crossref","unstructured":"Lewis, K, Eugster, E. Random luteinizing hormone often remains pubertal in children treated with the histrelin implant for central precocious puberty. J\u00a0Pediatr 2013;162:562\u20135. https:\/\/doi.org\/10.1016\/j.jpeds.2012.08.038.","DOI":"10.1016\/j.jpeds.2012.08.038"},{"key":"2026030907573189892_j_jpem-2025-0305_ref_026","doi-asserted-by":"crossref","unstructured":"Vargas Trujillo, M, Dragnic, S, Aldridge, P, Klein, KO. Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7\u00a0years or continuing beyond a chronological age of 10\u00a0years or a bone age of 12\u00a0years. J\u00a0Pediatr Endocrinol Metab 2021;34:733\u20139. https:\/\/doi.org\/10.1515\/jpem-2021-0114.","DOI":"10.1515\/jpem-2021-0114"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0305\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:58:33Z","timestamp":1773043113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jpem-2025-0305\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3,26]]}},"alternative-id":["10.1515\/jpem-2025-0305"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2025-0305","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}